top of page
logo

FDA's 2026 Food Priorities: A Mid-Year Check-In

Writer: Dan Simonsen
Dan Simonsen
Jun 30
3 min read

In February, FDA published its Human Foods Program 2026 Priority Deliverables — roughly 25 items spanning chemical safety, nutrition, and microbiological food safety. Almost five months in, the honest answer is: some of it is moving, some of it isn't, and which is which doesn't always match the order FDA listed them in.


Food Chemical Safety

GRAS reform is likely the most polarizing deliverable, and it has been since its final rule was released 10 years ago. Right now, a company can decide on its own that a new food ingredient is "Generally Recognized as Safe" and start selling it without telling FDA anything. The proposed rule would close that, requiring mandatory notification, a public inventory of GRAS substances, and a defined process for FDA to say no. Ingredients already cleared wouldn't be touched.

And this one's actually tracking close to schedule. The draft has been parked at OMB since December, and FDA's own food chemical safety director told an industry conference in February to expect it by early summer.[1] More telling: FDA didn't just talk, it opened a formal reassessment of the preservative BHA in March, then in May finalized its Systematic Post-Market Assessment framework and launched reviews of BHT and ADA on top of it.[2] Congress has four GRAS bills sitting in committee, and several states have stopped waiting on Washington entirely.[3]


Nutrition

The flagship commitment is Front-of-Package (FOP) labeling and it's also the clearest case of a 2026 priority stalling out quietly. FDA proposed it in January 2025 — a "Nutrition Info" box on the front of packages flagging saturated fat, sodium, and added sugar as low, medium, or high. The comment window closed last summer after one extension. All FDA actually committed to in 2026 was reading those comments and giving leadership some options to decide on. As of late May, that's exactly where it still sits. Trade press floated "spring 2026" as a finalization target. Spring's gone.[4]

Infant formula is the part of the nutrition pillar that's actually delivering. FDA released results from its largest-ever round of infant formula testing on April 29, and the heavy-metal exposure data it promised has kept showing up roughly on schedule.[5]


Microbiological Food Safety

BRIDGE — the plan to let state inspectors handle more routine facility checks so FDA can focus on imports and high-risk sites — is moving at exactly the pace its bureaucratic name implies. Phase 2, the "proof of process," started last October and runs through December 2027. Nobody's talking about national rollout before 2028.[6] There's a faster-moving piece attached to it, though: roughly 46 one-day inspectional assessments wrapped up by late April, almost all ending in no-action-indicated at lower-risk sites.[7] On imports, the shrimp and seafood safety work is happening through direct talks with India and Ecuador rather than through any new rule.


What This Means for Industry, and What 2027 Probably Brings

If you're running compliance for a food company, the split here is pretty clean. Chemical and ingredient work needs your attention now. Labeling and packaging teams have more room than the original 2026 timeline suggested. If you're leaning on self-affirmed GRAS status — and fermentation and alt-protein companies do this more than most — get a defensible safety dossier together before the rule actually publishes. Look-back provisions could turn this into a scramble for anyone who waits.


My guess for 2027: the GRAS rule is finalized or close to it, and someone's already in court arguing FDA never had the statutory authority to require notification in the first place — that fight has been brewing since the rule was first floated. Front-of-package labeling is probably still unfinished, or if it finally publishes, the real compliance dates get pushed out to 2029 or 2030 once the phase-in kicks in. BRIDGE is still mid-pilot, producing data nobody outside the trade press is reading yet. None of this is surprising once you notice the pattern: FDA moves where it already has authority to act, and stalls wherever a new rule means a fight in court or Congress. At least is going in the right direction.


Comments

bottom of page